Once aiming to double oncology pipeline, Servier's US branch touts rapid pace in building its foothold in the space
The US subsidiary of French pharma Servier has only been in existence for a touch under three years, but it hasn’t wasted a second — snapping up collaboration agreements and other deals that have propelled the company toward its main goal of becoming a major player in the oncological therapeutics industry.
David Lee, Servier Pharmaceuticals’ CEO, told Endpoints News that biopharma is making a clear shift toward targeting cancer therapies of all kinds, and Servier wants to be a part of it. Lee was named head of Servier’s US commercial branch when it launched in July 2018, and his goal was ambitious: double the company’s oncology portfolio by 2025.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.